Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2Q EARNINGS: Allergan boosts sales, cuts jobs, provokes Valeant

This article was originally published in Scrip

Executive Summary

With a 23.8% rise in second quarter earnings and a plan to cut $475m in 2015 expenses, including 1,500 jobs, Allergan thwarted an unsolicited $54bn acquisition bid by Valeant Pharmaceuticals with its continued assertion that the company doesn't need Valeant's money to increase its value.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts